Date | Compound | Laboratory | Indication | Type of Information |
---|---|---|---|---|
2014-12-16 | 2-hydroxymethyl-2-methoxymethyl-1-azabicyclo[2,2,2]octan-3-one | Aprea (Sweden) | ovarian cancer |
Granting of the orphan status in the EU |
2014-10-20 | Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase | Baxter (USA - IL) | primary immunodeficiency |
Product launch |
2014-12-09 | adalimumab | Zydus Cadila (India) | ankylosing spondylitis, juvenile idiopathic arthritis, psoriatic arthritis, rheumatoid arthritis | Product launch |
2018-01-08 | rurioctocog alfa pegol | Baxalta (USA - IL) now Shire (UK - USA) | hemophilia A | Granting of a Market Authorisation in the EU |
2017-01-17 | anthrax vaccine adsorbed | Emergent Biosolutions (USA - MD) | post-exposure prophylaxis of disease resulting from suspected or confirmed Bacillus anthracis exposure | Granting of the orphan status in the US |
2017-06-16 | abobotulinumtoxin A | Ipsen (France) | upper limb spasticity, pediatric patients with lower limb spasticity, spasticity in adults | Granting of a Market Authorisation in the US |
2014-12-16 | 5,5’-(4 (trifluromethyl)benzylazanediyl)bis(methylene)diquinolin-8-ol | Prof. Olivier Blin (France) | glioma |
Granting of the orphan status in the EU |
2015-02-02 | 5-[8-methyl-9-(1-methylethyl)-2-(4-morpholinyl)-9H-purin-6-yl]-2-pyrimidinamine | TMC Pharma Services (UK) Verastem (USA - CA) | malignant mesothelioma |
Granting of the orphan status in the US |
2014-12-16 | 5-bromo-N-(prop-2-yn-1-yl)-2-(1H-1,2,4-triazol-1-yl) pyrimidine-4,6-diamine | Palobiofarma (Spain) | Huntington’s disease |
Granting of the orphan status in the EU |
2014-12-16 | adenovirus serotype 5 containing partial E1A deletion and an integrin-binding domain | Alan Boyd Consultants (UK) | glioma |
Granting of the orphan status in the EU |
2014-12-16 | benserazide hydrochloride | Isabelle Ramirez | beta-thalassemia intermedia and major |
Granting of the orphan status in the EU |
2015-01-05 | amikacin sulfate | PlumeStars (Italy) | Pseudomonas aeuriginosa lung infections in cystic fibrosis | Granting of the orphan status in the US |
2014-12-16 | allogeneic CD34+ cells expanded ex vivo with an aryl hydrocarbon receptor antagonist | Novartis (Switzerland) | acute lymphoblastic leukaemia |
Granting of the orphan status in the EU |
2014-12-16 | allogeneic ex vivo-generated natural killer cells from CD34+ umbilical cord blood progenitor cells | IPD-Therapeutics (The Netherlands) | acute myeloid leukaemia |
Granting of the orphan status in the EU |
2014-12-16 | allogeneic adipose-derived adult mesenchymal stem cells contained in a fibrin-based bioengineered dermis | Biodan Yelah | epidermolysis bullosa |
Granting of the orphan status in the EU |
2014-12-16 | bevacizumab | Dr Sophie Dupuis-Girod (France) | hereditary haemorrhagic telangiectasia |
Granting of the orphan status in the EU |
2014-12-16 | chenodeoxycholic acid | Sigma-Tau Pharma UK (UK) Sigma-Tau Pharma (USA - MD) | inborn errors in primary bile acid synthesis |
Granting of the orphan status in the EU |
2014-12-22 | genetically modified serotype 5/3 adenovirus coding for granulocyte macrophage colony stimulating factor | Oncos Therapeutics (Finland) | malignant mesothelioma |
Granting of the orphan status in the US |
2014-12-16 | pegylated recombinant human hyaluronidase PH20 | Pharm. Research Associates (UK) Limited - Halozyme Therapeutics (USA - CA) | pancreatic cancer |
Granting of the orphan status in the EU |
2014-12-16 | plerixafor | Groupe d'étude des neutropénies (France) | WHIM syndrome |
Granting of the orphan status in the EU |
© 2024 Biopharmanalyses - Powered by Samacom+